Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, Perry A.

Am J Pathol. 2002 Aug;161(2):665-72.

2.

Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.

Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P.

Int J Cancer. 2005 Mar 20;114(2):249-56.

3.

Comparison of gene expression profiles between frozen original meningiomas and primary cultures of the meningiomas by GeneChip.

Sasaki T, Hankins GR, Helm GA.

Neurosurgery. 2003 Apr;52(4):892-8; discussion 898-9.

PMID:
12657186
4.

Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.

Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A.

Int J Oncol. 2009 Dec;35(6):1395-407.

PMID:
19885562
5.

Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.

Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A.

Cancer Res. 2005 Aug 15;65(16):7121-6.

6.

Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.

Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M.

Clin Cancer Res. 2010 Aug 15;16(16):4155-64. doi: 10.1158/1078-0432.CCR-10-0891.

7.

DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.

Menghi F, Orzan FN, Eoli M, Farinotti M, Maderna E, Pisati F, Bianchessi D, Valletta L, Lodrini S, Galli G, Anghileri E, Pellegatta S, Pollo B, Finocchiaro G.

Oncologist. 2011;16(10):1440-50. doi: 10.1634/theoncologist.2010-0249.

8.

Identification and characterization of genes differentially expressed in meningiomas.

Murphy M, Pykett MJ, Harnish P, Zang KD, George DL.

Cell Growth Differ. 1993 Sep;4(9):715-22.

9.

Meningioma transcript profiles reveal deregulated Notch signaling pathway.

Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, Riggins GJ, McDermott MW, Lal A.

Cancer Res. 2005 Jun 15;65(12):5070-5.

10.

Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B.

Neuro Oncol. 2010 Dec;12(12):1278-90. doi: 10.1093/neuonc/noq081.

11.

Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF.

Neuro Oncol. 2009 Aug;11(4):414-22. doi: 10.1215/15228517-2008-096.

12.

Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?

Fukami S, Riemenschneider MJ, Kohno M, Steiger HJ.

Brain Tumor Pathol. 2016 Jul;33(3):191-9. doi: 10.1007/s10014-016-0252-x.

PMID:
26942600
13.

Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.

Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, Perry A, Gutmann DH.

J Neuropathol Exp Neurol. 2011 Jan;70(1):1-12. doi: 10.1097/NEN.0b013e3182018f1c.

14.

Genetic alterations associated with progression and recurrence in meningiomas.

Pérez-Magán E, Campos-Martín Y, Mur P, Fiaño C, Ribalta T, García JF, Rey JA, Rodríguez de Lope A, Mollejo M, Meléndez B.

J Neuropathol Exp Neurol. 2012 Oct;71(10):882-93.

PMID:
22964784
15.

Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.

Johnson MD, O'Connell MJ, Pilcher W, Reeder JE.

J Neurosurg. 2010 May;112(5):934-9. doi: 10.3171/2009.7.JNS09726.

PMID:
19698046
16.

Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.

Nordqvist AC, Mathiesen T.

J Neurooncol. 2002 Mar;57(1):19-26.

PMID:
12125963
17.

High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression.

Esen H, Feyzioglu B, Erdi F, Keskin F, Kaya B, Demir LS.

Brain Tumor Pathol. 2015 Jul;32(3):195-201. doi: 10.1007/s10014-015-0212-x.

PMID:
25592259
18.

Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.

Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, Helm GA.

Neurosurgery. 2008 Oct;63(4):771-80; discussion 780-1. doi: 10.1227/01.NEU.0000325488.72518.9E.

PMID:
18981889
19.

DNA methylation in the malignant transformation of meningiomas.

Gao F, Shi L, Russin J, Zeng L, Chang X, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Mack WJ, Wang K.

PLoS One. 2013;8(1):e54114. doi: 10.1371/journal.pone.0054114.

20.

Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.

Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, Huang DP.

Neurosurgery. 1995 Oct;37(4):764-73.

PMID:
8559307
Items per page

Supplemental Content

Support Center